Skip to main content

Title III – Expansion of Productive Capacity and Supply

**Alt text:** Graphic titled “Investment Snapshot” showing a horizontal bar chart with two funding categories: **MCM Supply Chain – $37,162,696** and **Essential Medicines – $91,620,000**. To the right, a panel titled “Program Summary” displays **$128,782,696 Total Funding**.

The U.S. Department of Health and Human Services’ (HHS) Defense Production Act (DPA) Title III Program is responsible for strengthening the National Defense by enhancing the resiliency, diversity, and security of supply chains for health resources deemed essential to prepare for, respond to, and recover from chemical, biological, radiological, and nuclear (CBRN) threats, and emerging infectious diseases (EIDs).  

Programmatic Objectives

  • Expand domestic manufacturing capabilities: Enhance the ability of domestic manufacturers to produce and supply the Nation with health resources deemed by the President to be essential to the national defense. 

  • Reduce supply chain vulnerabilities: Mitigate risks associated with global supply chain disruptions. 

  • Promote innovation: Encourage the rapid development and commercialization of new technologies through research and development (R&D) initiatives. 

  • Ensure affordability and accessibility: Ensure that the health resources being produced and supplied to the Nation are affordable and widely available to all. 

Executive Orders Supported by HHS DPA Title III Program

The HHS DPA Title III Program supports and oversees contracts that further the goals defined in the following executive orders: 

DPA-Related Executive Orders

HHS will leverage Defense Production Act (DPA) Title III authorities to strategically expand critical production, commercialize R&D efforts, and scale emerging technologies to support domestic public health resource manufacturing capabilities.

Solicitations

Requests for Information (RFIs)

Status
 		Title
 		Response Date
 		Link
 
CurrentThere are no open RFIs at this time.——
Past
 		Public Health Industrial Base Capabilities and Capacities – Essential Medicines
 		Sept 26, 2025
 		View RFI
PastPublic Health Industrial Base – Anti-MicrobialsJan 22, 2025
 		View RFI
PastPublic Health Industrial Base – Essential Medicines & MCMsApr 5, 2024View RFI

 

Requests for Proposals (RFPs)
 

 

Status
 		Title
 		Response Date
 		Link
 
CurrentRequest for Project Proposals: Production of Drug Substances and Drug Products at Commercial Scale – Anti-Microbials and Large Volume ParenteralsFebruary 6, 2026March 9, 2026
Past
 		RPP-24-02-KSM-API: Drug Substances & Products at Commercial Scale
 		Mar 20, 2024
 		BioMap Consortium
PastRPP-24-03-Sterilization: Capacity for Vaccines & TherapeuticsMar 28, 20245
 		BioMap Consortium
 

Essential Medicines Portfolio

Medical Sterilization Portfolio

DPA-Related Executive Orders